Agile Capital Markets

Our latest deals : Domain Therapeutics ($42M series A), Ludocare (€4.2M Seed), Spine Innovations (M&A sell-side, un-disclosed amount), Neurofenix ($7M series A), Incepto (€27M series B)

CLIENT'S NEWS

acticor
admin

Acticor Biotech announces the enrollment of the first US patient in its Phase 2/3 study ACTISAVE for the treatment of stroke

Paris, France, September 26, 2022 – 06:00pm CEST – ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company developing innovative drugs for the treatment of cardiovascular emergencies, particularly stroke, today announced the enrollment of the first patient in the USA in its Phase 2/3 registration study ACTISAVE, which is evaluating glenzocimab in patients with acute ischemic stroke.

Read More »
DigitalHealth
admin

Incepto, the French Digital Health Specialist, is Raising €27 million to Support Its European Development

Founded in 2018, Incepto is a unique platform on the market that offers doctors and hospitals access to a portfolio of solutions based on artificial intelligence, designed to improve the quality of diagnoses, and save time for medical teams, without having to change equipment. In order to support its growth at a European scale, Incepto is raising €27 million today.

Read More »
FineHeart
admin

FineHeart certified ISO 13485 : 2016 for Medical Device Quality Management Systems

Bordeaux, France, September 5, 2022 – FineHeart S.A, a preclinical medical device company that has developed the ICOMS FLOWMAKER®, a fully Implantable Cardiac Output Management System designed to address the unmet need of patients suffering from severe heart failure, today announced its ISO 13485 : 2016 certification. This certifies the compliance of FineHeart’s quality management system with medical device industry regulations and has been issued following an audit by BSI, the independent, internationally recognized, accreditation organization.

Read More »

Acticor Biotech announces the enrollment of the first US patient in its Phase 2/3 study ACTISAVE for the treatment of stroke

Paris, France, September 26, 2022 – 06:00pm CEST – ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company developing innovative drugs for the treatment of cardiovascular emergencies, particularly stroke, today announced the enrollment of the first patient in the USA in its Phase 2/3 registration study ACTISAVE, which is evaluating glenzocimab in patients with acute ischemic stroke.

Learn more

Latest Insights

Cardiawave announces the authorization by the French National Agency for the Safety of Medicines and Health Products (ANSM) to proceed with a new clinical study in France

Paris, France, May 2, 2022 – Cardiawave SA, a deeptech medical device manufacturer that has developed VALVOSOFT® a revolutionary non-invasive medical device to treat aortic stenosis, the most prevalent heart valve disease in adults, today announced the authorization by the French National Agency for the Safety of Medicines and Health Products (ANSM) to proceed with a new clinical study in France.

Wefight annouces its partnership with Kiplin

We are proud to announce the launch of Vik Colorectal in Spain! Developed with the institutional support of Pierre Fabre Group, our newest virtual companion will support patients and their loved ones living with colorectal cancer!